The aim of the present study was to evaluate the capacity to expand of hematopoietic stem cell ( 
Ex vivo expansion of hematopoietic stem cells (HSC) has recently emerged as an alternative approach to providing enough cells for transplantation. [1] [2] [3] [4] [5] [6] Although the capacity of 14-day expanded cells to reconstitute long-term hemopoiesis has been questionned, 7 it is now clear that when added to a non-manipulated autograft, 2, 3, 5 or even when reinfused alone 6 expanded stem cells allow hematopoietic reconstitution or accelerate hematological reconstitution after highdose chemotherapy. We previously demonstrated that expansion rates are higher when CD34-selected cells were seeded instead of unmanipulated mononuclear cells. 4 Alternatively, immunoselection of CD34 + cells, [8] [9] [10] as well as combined CD19-negative/CD34-positive selection 11 have been proposed as methods for depletion of tumor cells from B lymphoma autografts, resulting in a reduction of lymphoma cells by 3 to 5 logs, as detected by cells bearing the bcl2/JH rearrangement resulting from the t(14;18) chromosomal translocation. 12 However, the persistence of tumor cells in several BM and PBPC CD34 + -selected cell grafts raises concern. Indeed, ex vivo expansion is aimed at stimulating normal HSCs, but the possible parallel expansion of tumor cells in the context of diseases where the autograft can be contaminated has to be considered.
High-dose chemotherapy with autologous HSC support can achieve increased response rates and tumor-free survival in patients with non-Hodgkin's lymphomas. 13, 14 Although the most likely cause of relapse after autologous HSC transplantation is the inability of treatment to eradicate the tumor remaining in the patient, recent studies indicate that reinfused tumor cells might at least participate in post-autograft relapse in AML, 15 CML 16 and neuroblastoma. 17 The most compelling data supporting the clinical usefulness of ex vivo marrow purging have been provided by Gribben et al 18 in 114 patients with B cell NHL, exhibiting a PCR-identifiable translocation of the bcl2 gene. Although the risk of tumor contamination has been shown to be lower in PBSCs than in BM, [19] [20] [21] it is well established that mobilization with growth factors leads to PBSC grafts containing increased quantities of tumor cells which are a potential source of relapse post transplantation. 20, 21 This emphasizes the need for purging tumor cells from autologous PBSC transplants as well as from marrow.
In the present study, we examined the expansion of HSC samples from eight patients with NHL, and followed in parallel the fate of tumor cells in four of eight samples still containing bcl2/JH + tumor cells after CD34
− /20 − /34 + cell selection, as well as in four of eight samples which were bcl2/JH − at culture initiation. Two of them were bcl2/JH − at harvesting and two were initially bcl2/JH + samples, but became bcl2/JH − after selection. This was done in order to check the possible reappearance of occult tumor cells after expansion culture. Expansion was carried out in conditions that we previously described, 22 as allowing high levels of expansion of normal precursors, progenitors and LTC-ICs. The role of Flt3-ligand, which was demonstrated to improve the amplification of HSCs, but also favors the growth of primitive B progenitor cells [23] [24] [25] was particularly examined.
Materials and methods

Patients
Progenitor/stem cells were collected from eight patients with NHL for autologous transplantation. Clinical characteristics are given in Table 1 . Bone marrow (BM) cells were collected in three patients (UPN 1 to 3). Peripheral blood stem cells (PBSC) were collected in five patients (UPN 4 to 8) after mobilization using an ACBVP (adriamycin, cyclophosphamide, vindesine, bleomycin, prednisone) chemotherapy regimen plus G-CSF (5 g/kg/day). At the time of collection, five patients were in complete remission (CR) and three in partial remission (PR). Seven of eight and two of eight had BM involvement at diagnosis and at harvesting respectively, as detected by histopathology. The bcl2/JH rearrangement status of the BM or the blood was studied at harvesting, after cell selection and after expansion. 
F = follicular; D = diffuse; CR = complete remission; PR = partial remission; BM = bone marrow; PB = peripheral blood.
Stem cell selection
CD34
+ cells were selected in four patients (UPN 1, 2, 5, 6) using the Ceprate SC stem cell concentration apparatus (CellPro, Bothell, WA, USA) as previously described. 17 
CD19
− /CD20 − /CD34 + cells were selected in four other patients (UPN 3, 4, 7, 8) using the Ceprate SC B cell depletion column (CellPro), according to the manufacturer's instructions. Briefly, the BM or PBSC buffy coat (BC) concentrate was incubated with 1 mg/ml biotinylated anti-CD19 and -CD20 antibodies for 30 min at room temperature and run on the B cell column. The non-adsorbed cells were collected. The B cell depleted bag was then incubated for 5 min at room temperature with 2.25 ml avidin (4.5 mg). Biotin (720 g) was then added, and a 15 min incubation was carried out; the 12.8 anti-CD34 MoAb was then added, followed by a 50 min incubation at room temperature. The cells were then processed on the CD34 column and CD19 − /20 − /34 + selected cells were collected. After processing, either CD34
+ or CD19 − /20 − /34 + cell samples were removed for flow cytometry analysis and bcl2/JH rearrangement assays. The remaining cells were resuspended in PBS containing 7.5% dimethylsulfoxide (B Braun Medical, Boulogne, France) and 2% HSA to a final volume of 4.5 ml, and cryopreserved in two 5-ml vials (Nalgene, Redmond, WA, USA), using a controlled-rate freezing method, and stored at −196°C to be later grafted. In addition, two samples containing 0.5 × 10 6 selected cells were frozen for further ex vivo expansion studies, after obtaining patient's informed consent.
Liquid cultures
Liquid ex vivo expansion cultures were carried out according to our previously described technique. 22 Briefly, 2.5 × 10 3 selected cells per well were suspended in six-well plates (Falcon, Heidelberg, Germany) in a mixture (1.5 ml per well) containing serum-free long-term culture medium (LTCM) and two combinations of cytokines. Cultures were incubated at 37°C in a 100% humidified, 5% CO 2 atmosphere for 10 days. The first of two cytokine combinations included the following recombinant human growth factors: stem cell factor (SCF) (100 ng/ml) (Amgen, Thousand Oaks, CA, USA), IL-3 (5 ng/ml) and IL-6 (10 ng/ml) (Sandoz, Basel, Switzerland), G-CSF (10 ng/ml) (Chugai Rhône Poulenc, Ukima, Japan) and Epo (0.5 U/ml) (Behring, Marburg, Germany). The second combination contained the five cytokines mentioned above plus Flt3-ligand (FL) (100 ng/ml) (Immunex, Washington, USA). On day 6, an equal volume of fresh LTCM and cytokines was added to each well. Total cells were collected on day 10, washed in Iscove's modified Dulbecco's medium (IMDM, Seromed, Biochrom, Berlin, Germany), counted by trypan blue exclusion and assayed for progenitor cells, LTC-IC, immunophenotype and bcl2/JH rearrangement.
Progenitor cell assays
Burst-forming unit-erythroid (BFU-E) and colony-forming unit granulocyte-macrophage (CFU-GM) cells were assayed in single-layer methylcellulose cultures according to previously described techniques. 25, 26 Briefly, 5 × 10 4 mononuclear cells (MNC) were plated in 35-mm Petri dishes in 1 ml aliquots of IMDM containing 30% fetal calf serum (FCS) (Gibco), detoxified BSA 10 mg/ml and 0.92% methylcellulose (Fluka, Buchs, Switzerland). Cells were stimulated with 20 ng/ml G-CSF and GM-CSF (Chugai Rhône-Poulenc), 10 ng/ml IL-3, 3 U/ml Epo and 50 ng/ml SCF. Cell concentrations were 0.5-1 × 10 3 CD34 + cells/ml for expansion input cells and 2 × 10 3 -5 × 10 4 cells/ml for expanded cells at day 10. Three dishes were plated for each culture. BFU-E and CFU-GM were scored on day 14 of culture.
Evaluation of LTC-ICs in limiting dilution assay
Assay for LTC-ICs was performed by limiting dilution analysis according to the method of Sutherland et al 27, 28 slightly modified. 22 Unirradiated murine MS 5 stromal feeder cells were pre-established in 96-well plates (6 × 10 3 cells/well in 100 l). To avoid early detachment of the stromal layer, plastic wells were precoated with 1% gelatin before seeding of the stromal cells. BM mononuclear cells (MNC) were cocultured at limiting dilution (10 2 to 10 4 cells/well) in 96-well plates precoated with MS5 cells in 100 l LTC medium (IMDM supplemented with 2.6 mm l-glutamine, 40 g/ml myoinositol, 10 g/ml folic acid, 1.6 × 10 −4 m monothioglycerol, 1.5 U/ml heparin, 40 U/ml penicillin, 40 g/ml streptomycin, FCS 12.5% and horse serum 12.5%). For each experiment, 20 to 50 wells per concentration were initiated. Cultures were kept for 2-3 days at 37°C and subsequently transferred to 33°C, 5% CO 2 . All cultures were fed every week by half-medium change.
After 5 weeks of culture, the progenitor content of each well was scored by overlaying with methylcellulose medium containing SCF, IL-3, G-CSF, GM-CSF and Epo as described above. The LTC-IC frequency was determined by scaling the cultures down to a volume of 100 l in 96-well microtiter plates and performing limiting dilution assays with 20 to 50 replicates per step. Dilution steps were 100, 50, 25, 10 and five cells/well for the CD34 + or CD19 − /20 − /34 + fraction of day 0. The expanded population was assayed from 100 to 8 × 10 4 cells/well, taking into
Bone Marrow Transplantation account the cell expansion rate. The absolute number of LTC-ICs was calculated as the concentration of cells that gave 37% negative wells, using Poisson statistics. The CFC-generating capacity of LTC-ICs was assessed by scoring the progenitors from all the dilutions that gave 37% negative wells (i.e. total CFC produced in n wells at dilutions that gave 37% negative wells/total LTC-ICs in n wells, where total LTC-ICs is obtained from the frequency of LTC-ICs and the total number of cells in the experiment). Clonogenic cells (CFU-GM + BFU-E + CFU-GEMM) were scored on the 14th day of incubation at 37°C with 5% CO 2 to evaluate the number of clonogenic progenitors.
Flow cytometry analysis
The initial BC and the selected fractions were studied for the CD34 + cell content using the monoclonal antibody PEanti CD34 (HPCA2), IgG1 (Becton Dickinson, BD). Mouse IgG1-FITC/IgG1-PE was used as the isotype control. The flow cytometric analysis of cells was performed with a FACSort (BD) coupled with CellQuest software. At least 20 000 cells were analyzed. The morphological forward and side scatter parameters allowed exclusion of debris from the analysis.
Study of minimal residual disease by PCR detection of bcl2/JH rearrangement
For molecular studies, the same number of cells, obtained either from harvested cells or from CD34 + and CD19 − /20 − /34 + cell fractions, was used. High molecular weight DNA was extracted according to standard methods and the amplification of the bcl2/JH rearrangement at the major breakpoint region (MBR) was performed by nested PCR according to a previously described technique. 8 For each experiment, a positive control consisting of DNA from RL cells, a lymphoma cell line with a t(14;18) translocation, and a negative control consisting of the PCR buffer with heat-inactivated proteinase K were performed. Each sample was analyzed at least twice. The sensitivity of the nested PCR, determined by serial dilutions of bcl2/JH + RL cells in normal bone marrow mononuclear cells followed by subsequent extraction of DNA, was approximately 1 in 10 5 cells for a final number of 10 6 cells. No increase in sensitivity was obtained by hybridization with an internal probe.
Results
Cell selection
Data before and after CD34
+ cell selection (UPN 1, 2, 5, 6) or CD19 − /20 − /34 + cell selection (UPN 3, 4, 7, 8) are given in Table 2 . The CD34 + cell purity achieved after single or double selection ranged from 17% to 99% (mean: 53%; median: 48%). Interestingly, CD34
+ cell purity was higher after single selection (36, 51, 73 and 99%) than after double selection (17, 42, 45 and 63%).
Before cell expansion, the input samples contained a Table 2 . The mean (range) amplification with the cocktail of cytokines not containing Flt3-L was 833-(153-2658), 6.6-(1.5-12.6), 4.6-(0.6-13.1), 1.8-(0.5-3.7) fold for total nucleated cells, CFUGMs, BFU-Es and LTC-ICs (five of eight samples tested), respectively. Medians were respectively 479, 4.7, 4, and 1.3. When Flt3-L was present in the culture medium, the mean expansion increased to 1095-(median: 768), 31-(median: 23), 15-(median: 17) and 3-(median: 2) fold for total cells, CFU-GMs, BFU-Es and LTC-ICs, respectively. The percent of CD34 + cells in the final expanded product ranged from 0.05% to 0.9% (median 0.35) and from 0.05% to 0.5% (median 0.2) in the absence or in the presence of Flt3-L. The corresponding total number of CD34 + cells, respectively, increased to a median of 4.0-and 2.9-fold in the absence or in the presence of Flt3-L. However, the inherent imprecision of measuring CD34
+ cells in expansion products when median CD34 + percentages were of the order of 0.2 to 0.35% makes calculation of the expansion rate highly imprecise and leads to non-significance in the recovery determination. Overall, the mean increase in expansion rates with S36EGF stimulating conditions, as compared to those with S36EG, was 1.5 times (range: 1.0-2.3) for total cells (P Ͻ 0.02), 5.5 times (range: 2.2-14.8) for CFU-GMs (P Ͻ 0.02), 2.7 times (range: 1.2-6.9) for BFU-Es (P Ͻ 0.02), and 1.7 times (range: 1.3-2.7) for LTC-ICs. The difference in the numbers of LTC-ICs was not statistically significant in the two experimental conditions, although they were higher in the presence of Flt3-L in the five of five tested samples. It is notable that expansion of CFU-GM and BFU-E in the presence of Flt3-L was higher after single selection than after double selection.
Detection of bcl2/JH+ cells (Table 3)
All the samples were studied for the bcl2/JH marker at harvesting, after selection and after expansion under S36EG ± F stimulation conditions. Before selection, six samples (from patients 2, 3, 5, 6, 7 and 8) contained bcl2/JH + cells; one BM (patient 1) and one PBSC (patient 4) bcl2/JH-negative samples were used as controls, to check that the selection and/or the expansion would not make initially undetectable tumor cells reappear. After selection, Table 3 Presence of bcl2/JH + cells from BM or PBSC before and after single or double selection, and after expansion + cell selection, and 2/3 after CD19 − /20 − /34 + cell selection). The two bcl2/JH-negative control samples remained negative after selection.
So, of the eight samples submitted to ex vivo expansion, half contained bcl2/JH + cells and half did not. After expansion, the bcl2/JH marker was not detectable in any sample whether or not Flt3-L was present in the cytokine cocktail. In order to increase the probability of detecting bcl2/JH cells in the final expanded product, DNA extraction from a second aliquot of expanded cells of all samples was carried out and bcl2/JH rearrangement detection was performed 10 times for each sample: bcl2/JH + cells were never detected in these 10 tests.
Discussion
The present study was undertaken to determine the capacity of ex vivo expansion of selected HSCs from patients with NHL and to follow the fate of bcl2/JH + lymphoma cells contaminating BM and PBSC selected cell grafts. We have previously reported 22 that ex vivo experimental conditions using a cytokine combination of SCF, IL-3, IL-6, Epo, G-CSF and Flt-3 ligand efficiently expanded normal bone marrow cells to medians of 2428-fold for total cells, 42-fold for CFU-GM, 11-fold for BFU-E and three-fold for LTC-IC. We have recently shown the long-term multilineage reconstitution capacity of such ex vivo expanded cells. 29 These data established myeloid engraftment in the marrow of the NOD/SCID mice, 6 weeks and 5 months after transplantation, by (1) the presence of CD15 and GPA positive precursor cells; (2) the capacity of CD45 + cells to give rise to CFU-GM/BFU-E progenitors, and (3) the capacity of CD34 + /CD38 − sorted cells to generate LTC-IC with conservation of their clonogenic capacity. In that study we correlated the high levels of LTC-IC and E-LTC-IC in the expanded populations to their capacity to reconstitute long-term hematopoiesis in the murine model. In the present study, we showed that these conditions can be applied to BM or PBSC collections from NHL patients resulting in median expansion levels of 768-, 23-, 17-and two-fold for total cells, CFU-GMs, BFU-Es and LTC-ICs, respectively, and suggesting a potential clinical application of this approach. The lower median expansion levels obtained with cells from NHL patients, as compared to normal BM cells (except for BFU-Es), could be due to the previous chemotherapeutic treatments given to the patients or to the disease itself. A similar defect in expansion potential was recently reported for bone marrow from patients with AML. 28 BM products from patients with follicular lymphoma contain bcl2/JH + tumor cells in the majority of cases. 30 Moreover, it has been recently shown that after mobilization there is no difference in the number of bcl2/IgH + tumor cells present in BM vs PBSC from NHL patients. 31 Thus, in expansion of HSC from NHL patients, careful attention should be given to the possible amplification of detectable or occult tumor cells. It is known that CD34 + cell selection (which is part of our expansion procedure) does not always adequately + selected cells using a cocktail of SCF, IL-1, IL-3 and IL-6 which, in contrast to our experimental conditions, poorly expanded progenitors: the total cells and CFU-GMs were expanded 15-and four-fold, respectively, while BFU-E and CFU-GEMM were lost at day 14 of the culture. Of interest is that in their expansion conditions, a bcl2/JH-negative sample became positive at the end of the culture, while in our experimental conditions, this never occurred. However, the non-detection of bcl2/JH + cells in the final expanded product cannot exclude the presence of occult tumor cells. Indeed, since the sensitivity of the PCR technique used is in the range of 10 −5
, the expansion of total nucleated cells may have diluted tumor cells down to an undetectable level. Studies are now in progress in our laboratory to quantify the bcl2/JH contamination in the expanded product using quantitative real-time PCR analysis. However our results clearly indicate that the tumor cell/normal HSC ratio was decreased by the expansion procedure and that expansion can confer a proliferative advantage of hematopoietic cells without an apparent risk of concomitantly expanding residual bcl2/JH + cells. Disappearance of detectable tumor cells by ex vivo expansion was also observed in PBSCs artificially contaminated by tumour, 36 as well as in some cases of breast cancer PBSCs. 37 On the contrary, Von Riet et al 38 have reported that cell suspensions from patients with multiple myeloma that were expanded with a cytokine cocktail of IL-1, IL-3, G-CSF and GM-CSF showed persistent tumor contamination in two-thirds of the evaluable cases at the peak of CFU-GM output.
Although the role of reinfused tumor cells in the outcome of patients after autografting is still a matter of debate, it appears from these data that ex vivo liquid cultures of CD34-selected cells may be of interest for autografting in patients with NHL, since expansion of the normal progenitor/stem cell pools was not accompanied by a parallel expansion of tumor cells and, indeed, was even associated with a reduction in the original contaminating tumor load.
